About ParAllele BioScience
ParAllele BioScience is a company based in San Francisco (United States) founded in 2001 by Malek Faham was acquired by Affymetrix in May 2005.. ParAllele BioScience has raised $22.5 million across 2 funding rounds from investors including Abingworth, Affymetrix and Mohr Davidow Ventures. ParAllele BioScience operates in a competitive market with competitors including GSK, Metabolon, Avidity Biosciences, Sutro Biopharma and Maze Therapeutics, among others.
- Headquarter San Francisco, United States
- Founders Malek Faham
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$22.5 M (USD)
in 2 rounds
-
Latest Funding Round
$6 M (USD), Debt – Convertible
Apr 14, 2005
-
Investors
Abingworth
& 4 more
-
Employee Count
Employee Count
-
Acquired by
Affymetrix
(May 31, 2005)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of ParAllele BioScience
ParAllele BioScience has successfully raised a total of $22.5M across 2 strategic funding rounds. The most recent funding activity was a Debt – Convertible round of $6 million completed in April 2005. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Debt – Convertible — $6.0M
-
First Round
First Round
(23 Sep 2003)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2005 | Amount | Debt – Convertible - ParAllele BioScience | Valuation |
investors |
|
| Sep, 2003 | Amount | Series B - ParAllele BioScience | Valuation | Mohr Davidow Ventures |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in ParAllele BioScience
ParAllele BioScience has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Abingworth, Affymetrix and Mohr Davidow Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are managed in technology and healthcare sectors by this firm.
|
Founded Year | Domain | Location | |
|
Early stage venture capital firm investing in US
|
Founded Year | Domain | Location | |
|
Venture capital investments in technology startups and entrepreneurs.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by ParAllele BioScience
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - ParAllele BioScience
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Parallele Bioscience Comparisons
Competitors of ParAllele BioScience
ParAllele BioScience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Metabolon, Avidity Biosciences, Sutro Biopharma and Maze Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| domain | founded_year | HQ Location |
Solutions for biomarker discovery and diagnostic testing are provided.
|
|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| domain | founded_year | HQ Location |
Genetic biomarkers are developed for neurological, metabolic, and renal diseases.
|
|
| domain | founded_year | HQ Location |
Yeast cells are genetically engineered to produce medicinal products.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about ParAllele BioScience
When was ParAllele BioScience founded?
ParAllele BioScience was founded in 2001 and raised its 1st funding round 2 years after it was founded.
Where is ParAllele BioScience located?
ParAllele BioScience is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Is ParAllele BioScience a funded company?
ParAllele BioScience is a funded company, having raised a total of $22.5M across 2 funding rounds to date. The company's 1st funding round was a Series B of $22.5M, raised on Sep 23, 2003.
What does ParAllele BioScience do?
ParAllele BioScience was focused on providing genetic discovery solutions to the life science research, pharmaceutical, and diagnostic sectors. Its products and services were based on the approach that leverages novel biochemical processes and discovers and analyze minute variations in the human genome which contribute to disease risk, prognosis, and drug response. It also had research collaborations with multiple large pharmaceutical companies and prestigious academic and government institutions. Its proprietary Molecular Inversion Probe assay, also known as MIP technology was used by many biotechnology companies including Affymetrix. MIP involves capture by circularization technique, wherein during hybridization with the target the probes get circularized, increasing the specificity and scalability of the assay. In 2005, Affymetrix acquired ParAllele.
Who are the top competitors of ParAllele BioScience?
ParAllele BioScience's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Who are ParAllele BioScience's investors?
ParAllele BioScience has 5 investors. Key investors include Abingworth, Affymetrix, Mohr Davidow Ventures, Index Ventures, and Versant Ventures.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.